Loading...
•
Mar 31, 2025
Mirum Pharmaceuticals Q1 2025 Earnings Report
Mirum Pharmaceuticals reported financial results for the first quarter of 2025
Key Takeaways
Mirum Pharmaceuticals had a strong start to 2025 with commercial growth and pipeline advancements. Total revenue for Q1 2025 was $111.6 million, a significant increase from the same period in the previous year. The company also raised its full-year 2025 revenue guidance.
First quarter 2025 total revenue reached $111.6 million.
Full year 2025 revenue guidance was increased to $435 to $450 million.
LIVMARLI oral tablet formulation received FDA approval.
Enrollment in the VISTAS study for PSC is expected to be completed in the third quarter of 2025.
Forward Guidance
Mirum Pharmaceuticals increased its full year 2025 total revenue guidance.
Positive Outlook
- Full year 2025 revenue guidance increased to $435 to $450 million.
- VISTAS study in PSC expected to complete enrollment in third quarter of 2025.
- LIVMARLI oral tablet formulation FDA approved.
- LIVMARLI approved in Japan for ALGS and PFIC.
- CTEXLI (chenodiol) approved in the US for cerebrotendinous xanthomatosis.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...